Toll-like receptor 2 and -4 are involved in the pathogenesis of the Guillain-Barré syndrome

Du,Yamei; Zhang,Guojun; Zhang,Zaiqiang; Wang,Qian; Ma,Ruimin; Zhang,Limin; Fan,Fei; Li,Youran; Wang,Meng; Lv,Hong; Kang,Xixiong

doi:10.3892/mmr.2015.3730

August-2015 Volume 12 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2015 Volume 12 Issue 2

Full Size Image

Article

Toll-like receptor 2 and -4 are involved in the pathogenesis of the Guillain-Barré syndrome

Authors:
- Yamei Du
- Guojun Zhang
- Zaiqiang Zhang
- Qian Wang
- Ruimin Ma
- Limin Zhang
- Fei Fan
- Youran Li
- Meng Wang
- Hong Lv
- Xixiong Kang
View Affiliations / Copyright

Affiliations: Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Pages: 3207-3213
|
Published online on: May 5, 2015

https://doi.org/10.3892/mmr.2015.3730
Expand metrics +

Abstract

Guillain-Barré syndrome (GBS) is an autoimmune disorder of the peripheral nervous system characterized by weakness in the limbs. To date, numerous hypotheses have been suggested to explain the pathogenesis of GBS; however, the pathogenesis of GBS remains to be elucidated. The aim of the present study was to investigate the association between Toll‑like receptor (TLR) 2, TLR4 and GBS. Therefore, the mRNA of TLR2, TLR4, myeloid differentiation factor (MyD)88 and nuclear factor (NF)‑κB of peripheral blood mononuclear cells (PBMCs) in patients with GBS and healthy controls was assessed. To confirm the function of TLR2 and TLR4 in the pathogenesis of GBS, PBMCs derived from patients with GBS and healthy controls were cultured with various TLR agonists. The levels of tumor necrosis factor (TNF)‑α and interleukin (IL)‑1β were measured in the culture supernatant and fasting serum was obtained for the detection of anti‑ganglioside antibodies. The results revealed that the mRNA levels of TLR2, TLR4, MyD88 and NF‑κB were significantly increased in patients with GBS compared with those in healthy controls (P=0.003, 0.017, 0.032 and 0.015, respectively). PBMCs from patients with GBS secreted higher levels of TNF‑α and IL‑1β than those from control subjects. The positive rate of immunoglobulin (Ig)G and IgM anti‑ganglioside antibodies in patients with severe GBS was 42.86%, which was markedly higher than rates found in patients with mild GBS (9.09 and 18.18%, respectively). The results of the present study demonstrated that TLR2 and TLR4 are involved in the pathogenesis of GBS and that they and their associated signaling pathways may be targets for the treatment of GBS.

View Figures

View References

1	McGrogan A, Madle GC, Seaman HE and de Vries CS: The epidemiology of Guillain-Barŕe syndrome worldwide. A systematic literature review. Neuroepidemiology. 32:150–163. 2009. View Article : Google Scholar
2	Huang WT, Yang HW, Liao TL, et al: Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study. PLoS One. 8:e588272013. View Article : Google Scholar : PubMed/NCBI
3	Salmon DA, Proschan M, Forshee R, et al: Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 381:1461–1468. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zhang D, Zhang G, Hayden MS, et al: A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 303:1522–1526. 2004. View Article : Google Scholar : PubMed/NCBI
5	Eom SH, Gu GJ, Suh CW, et al: Suppression of inducible nitric oxide synthase expression induced by Toll-like receptor agonists by (E)-1-(2-(2-nitrovinyl)phenyl) pyrrolidine. Int Immunopharmacol. 17:205–209. 2013. View Article : Google Scholar : PubMed/NCBI
6	Santaolalla R, Sussman DA, Ruiz JR, et al: TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One. 8:e632982013. View Article : Google Scholar
7	Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25:187–191. 2000. View Article : Google Scholar : PubMed/NCBI
8	Zhang ZY, Zhang Z and Schluesener HJ: FTY720 attenuates lesional interleukin-17 (+) cell accumulation in rat experimental autoimmune neuritis. Neuropathol Appl Neurobiol. 35:487–495. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang ZY, Zhang Z and Schluesener HJ: Toll-like receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis. Neuroscience. 159:136–142. 2009. View Article : Google Scholar : PubMed/NCBI
10	Reynolds JM, Pappu BP, Peng J, et al: Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity. 32:692–702. 2010. View Article : Google Scholar : PubMed/NCBI
11	Islam Z, Gilbert M, Mohammad QD, et al: Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies. PLoS One. 7:e439762012. View Article : Google Scholar
12	Heikema AP, Koning RI, Duarte dos Santos Rico S, et al: Enhanced sialoadhesin-dependent uptake of Guillain-Barre syndrome-associated Campylobacter jejuni strains by human macrophages. Infect Immun. 81:2095–2103. 2013. View Article : Google Scholar : PubMed/NCBI
13	Nakamura M, Funami K, Komori A, et al: Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers. Hepatol Int. 2:222–230. 2008. View Article : Google Scholar : PubMed/NCBI
14	Kaida K, Ariga T and Yu RK: Antiganglioside antibodies and their pathophysiological effects on Guillain-Barr e syndrome and related disorders-A review. Glycobiology. 19:676–692. 2009. View Article : Google Scholar : PubMed/NCBI
15	Hans M and Hans VM: Toll-like receptors and their dual role in periodontitis: a review. J Oral Sci. 53:263–271. 2011. View Article : Google Scholar : PubMed/NCBI
16	Deng YN and Zhou WB: Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis. Neuroimmunomodulation. 14:337–343. 2007. View Article : Google Scholar
17	Marta M, Andersson A, Isaksson M, et al: Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol. 38:565–575. 2008. View Article : Google Scholar : PubMed/NCBI
18	van Koningsveld R, Steyerberg EW, Hughes RA, et al: A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 6:589–594. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wang YZ, Liang QH, Ramkalawan H, et al: Expression of Toll-like receptors 2, 4 and 9 in patients with Guillain-Barré syndrome. Neuroimmunomodulation. 19:60–68. 2012. View Article : Google Scholar
20	Kusunoki S: Antiglycolipid antibodies in Guillain–Barré syndrome and autoimmune neuropathies. Am J Med Sci. 319:234–239. 2000. View Article : Google Scholar : PubMed/NCBI
21	Arcila-Londono X and Lewis RA: Guillain-Barré syndrome. Semin Neurol. 32:179–186. 2012. View Article : Google Scholar : PubMed/NCBI
22	Komatsuda A, Wakui H, Iwamoto K, et al: Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythe-matosus. Clin Exp Immunol. 152:482–487. 2008. View Article : Google Scholar : PubMed/NCBI
23	Papadimitraki ED, Choulaki C, Koutala E, et al: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 54:3601–3611. 2006. View Article : Google Scholar : PubMed/NCBI
24	Gries M, Davies L, Liu Y, Bachhuber A, et al: Response of Toll-like receptors in experimental Guillain-Barré syndrome: a kinetic analysis. Neurosci Lett. 518:154–160. 2012. View Article : Google Scholar : PubMed/NCBI
25	Matsui H, Ohgomori T, Natori T, et al: Keratan sulfate expression in microglia is diminished in the spinal cord in experimental autoimmune neuritis. Cell Death Dis. 4:e9462013. View Article : Google Scholar : PubMed/NCBI
26	Orlikowski D, Chazaud B, Plonquet A, et al: Monocyte chemoat-tractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis. J Neuroimmunol. 134:118–127. 2003. View Article : Google Scholar : PubMed/NCBI
27	Boyle K, Azari MF, Cheema SS and Petrato SS: TNF alpha mediates Schwann cell death by upregulating p75NTR expression without sustained activation of NFkappaB. Neurobiol Dis. 20:412–427. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kurz M, Pischel H, Hartung HP and Kieseier BC: Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system. J Peripher Nerv Syst. 10:311–318. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zhang J, Dong H, Li B, et al: Association of tumor necrosis factor polymorphisms with Guillain-Barré syndrome. Eur Neurol. 58:21–25. 2007. View Article : Google Scholar
30	Zhang HL, Hassan MY, Zheng XY, et al: Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages. PLoS One. 7:e381572012. View Article : Google Scholar
31	Hayashi R, Xiao W, Kawamoto M, et al: Systemic glucocorticoid therapy reduces pain and the number of endoneurial tumor necrosis factor-alpha (TNF alpha)-positive mast cells in rats with a painful peripheral neuropathy. J Pharmacol Sci. 106:559–565. 2008. View Article : Google Scholar : PubMed/NCBI
32	Sivieris, Ferrarini AM, Lolli F, et al: Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J Neurol Sci. 147:93–95. 1997. View Article : Google Scholar
33	Vaishnavi C, Behura C, Prabhakar S, Sharma A and Kharbanda P: Anti-ganglioside antibodies in patients with Guillain Barré syndrome and other neurological disorders. Indian J Med Microbiol. 31:177–179. 2013.PubMed/NCBI
34	Chatani H, Tanaka M, Nagata T, et al: Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immuno-globulin G anti-N-acetylgalactosaminyl-GD1a antibody. J Clin Neurosci. 21:170–172. 2014. View Article : Google Scholar
35	Kaida K, Ariga T and Yu RK: Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders-a review. Glycobiology. 19:676–692. 2009. View Article : Google Scholar : PubMed/NCBI
36	Jacobs BC, van Doorn PA, Schmitz PI, et al: Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol. 40:181–187. 1996. View Article : Google Scholar : PubMed/NCBI
37	Koga M, Gilbert M, Takahashi M, et al: GQ1b-seronegative Fisher syndrome: clinical features and new serological markers. J Neurol. 259:1366–1374. 2012. View Article : Google Scholar : PubMed/NCBI
38	Lehmann HC, Lopez PH, Zhang G, Ngyuen T, Zhang J, et al: Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci. 27:27–34. 2007. View Article : Google Scholar : PubMed/NCBI
39	Sheikh KA and Zhang G: An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome. F1000 Biol Rep. 2:212010.